TUESDAY, June 9, 2026 (HealthDay News) — Finerenone produced a slower decline in eGFR than placebo in adults with chronic kidney disease (CKD) without diabetes, according to a study published online June 4. New England Journal of Medicine which corresponds to the annual congress of the European Association of Europe, which was held in Glasgow from June 3 to 6.
Hiddo J.L. Herspink, Ph.D., from the University of Groningen Medical Center in the Netherlands and colleagues randomly assigned 1,584 non-diabetic adults with CKD and albuminuria who were using a renin-angiotensin system inhibitor to receive firenone (10 or 20 mg per day) and placebo (793 participants, respectively).
The researchers found that the mean annual rate of change in eGFR from baseline to month 32 was -3.3 and -4.0 mL/min/1.73 m.2with firenone and placebo, respectively (difference, 0.7). The risk of composite renal or cardiovascular events was significantly lower with fenrenone compared with placebo in a prespecified hierarchical analysis (hazard ratio, 0.77). Hyperkalemia was the most common adverse event (17.0 and 13.3 percent with firenone and placebo, respectively); Events of hyperkalemia led to discontinuation of the trial regimen in 1.5 and 0.1 percent of patients receiving Firenone and placebo, respectively, and hospitalization in 0.9 and 0.6.
“The results show that fenrenone significantly preserved renal function and reduced the risk of cardiovascular and renal outcomes with continuous exposure in pretreated subgroups, supporting its widespread use in these patients,” Herspink said.
Several authors disclosed ties to biopharmaceutical companies, including Bayer, which manufactures firenone and funded the research.
Abstract / Full Text (subscription or payment may be required)
